+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

KYORIN Holdings Inc (4569) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 47 Pages
  • June 2022
  • GlobalData
  • ID: 4418440
KYORIN Holdings Inc (4569) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

KYORIN Holdings Inc (Kyorin) is a holding company that controls, administers and supports its group companies that conduct various businesses by holding the shares of those companies. The company through its subsidiaries carries out the discovery, development, manufacturing and sale of pharmaceuticals including new ethical drugs, generic drugs and the over the counter (OTC) drugs, diagnostics, reagents, intermediates, diagnostics, industrial chemicals and other products. The company markets its product under Kipres, Mucodyne, Pentasa, Uritos, Ketas, Flutiform, Milton, Rubysta and other brands. The company operates is business through its subsidiaries including KYORIN Pharmaceutical Co Ltd, KYORIN Rimedio Co Ltd and KYORIN Pharmaceutical Group Facilities Co Ltd in Japan. Kyorin is headquartered in Tokyo, Japan.

KYORIN Holdings Inc Key Recent Developments

May 11,2022: Kyorin Pharmaceutical Co. Notice regarding changes in officers
Apr 26,2022: Kyorin Holdings Revision of Consolidated Financial Forecasts for Fiscal Year Ended March 31, 2022
Feb 04,2022: Kyorin Holdings announces Financial Results for the 3rd Quarter of the Fiscal Year Ending March 2022
May 11,2021: Kyorin Remedio Notice regarding changes in officers

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
  • Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
  • Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
  • Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
  • Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
KYORIN Holdings Inc - Key Facts
KYORIN Holdings Inc - Key Employees
KYORIN Holdings Inc - Key Employee Biographies
KYORIN Holdings Inc - Major Products and Services
KYORIN Holdings Inc - History
KYORIN Holdings Inc - Company Statement
KYORIN Holdings Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 - Company Analysis
Company Overview
KYORIN Holdings Inc - Business Description
Product Category: Generic Drugs
Overview
Performance
Key Stats
Product Category: New Ethical Drugs
Overview
Performance
Key Stats
R&D Overview
KYORIN Holdings Inc - Corporate Strategy
KYORIN Holdings Inc - SWOT Analysis
SWOT Analysis - Overview
KYORIN Holdings Inc - Strengths
KYORIN Holdings Inc - Weaknesses
KYORIN Holdings Inc - Opportunities
KYORIN Holdings Inc - Threats
KYORIN Holdings Inc - Key Competitors
Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
KYORIN Holdings Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
May 11, 2022: Kyorin Pharmaceutical Co. Notice regarding changes in officers
Apr 26, 2022: Kyorin Holdings Revision of Consolidated Financial Forecasts for Fiscal Year Ended March 31, 2022
Feb 04, 2022: Kyorin Holdings announces Financial Results for the 3rd Quarter of the Fiscal Year Ending March 2022
May 11, 2021: Kyorin Remedio Notice regarding changes in officers
Section 6 - Appendix
Methodology
Ratio Definitions
About the Publisher
Contact Us
Disclaimer
List of Tables
KYORIN Holdings Inc, Key Facts
KYORIN Holdings Inc, Key Employees
KYORIN Holdings Inc, Key Employee Biographies
KYORIN Holdings Inc, Major Products and Services
KYORIN Holdings Inc, History
KYORIN Holdings Inc, Subsidiaries
KYORIN Holdings Inc, Key Competitors
KYORIN Holdings Inc, Ratios based on current share price
KYORIN Holdings Inc, Annual Ratios
KYORIN Holdings Inc, Interim Ratios
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
KYORIN Holdings Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
KYORIN Holdings Inc, Performance Chart (2018 - 2022)
KYORIN Holdings Inc, Ratio Charts
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Torii Pharmaceutical Co Ltd
  • Teijin Ltd
  • Santen Pharmaceutical Co Ltd
  • Nippon Shinyaku Co Ltd
  • Mochida Pharmaceutical Co Ltd
  • Astellas Pharma Inc